The boom of copyright’s drug initially fueled significant growth in the medicinal sector, producing a understanding of substantial returns. However, funding in companies heavily reliant on top-selling drugs like Sildenafil presents significant risks. Exclusive rights expiration has led alternativ

The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for game-changing treatments and impressive returns